Status In progress
Process MTA
ID number 56

Provisional Schedule

Final appraisal determination 15 February 2018 - 01 March 2018
Expected publication 28 March 2018

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Genzyme Therapeutics (vandetanib)
  Ipsen (cabozantinib)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Association for Multiple Endocrine Neoplasia Disorders
  Butterfly Thyroid Cancer Trust
Professional groups Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated public health groups None
Comparator companies Genzyme Therapeutics (vandetanib)
  Ipsen (cabozantinib)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
15 February 2018 The scope for this technology appraisal includes vandetanib. NICE is not currently in a position to release any recommendations on vandetanib. A separate document with the committee’s recommendations on vandetanib will be released at a later date.
09 January 2018 Committee meeting: 3
22 December 2017 Ipsen requested to submit an updated value proposition for cabozantinib, which has been accepted. This will be discussed at the technology appraisal committee on 9 January 2018 in a closed, private session.
27 September 2017 Committee meeting: 2
23 August 2017 - 14 September 2017 Appraisal consultation
26 July 2017 Committee meeting: 1
14 June 2017 Assessment report sent for information
20 October 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance